Welcome to our dedicated page for Viemed Healthcare SEC filings (Ticker: VMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Viemed Healthcare, Inc. (VMD) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, along with AI-generated summaries to help interpret complex documents. Viemed is incorporated in British Columbia, Canada and files with the SEC under Commission File Number 001-38973, with its common shares listed on NASDAQ under the symbol VMD.
For a company operating as an in-home clinical care provider of post-acute respiratory healthcare equipment and services in the United States, core filings such as the annual report on Form 10-K and quarterly reports on Form 10-Q are central resources. These documents typically contain detailed information on revenue from respiratory equipment and services, operating expenses, cash flows, and risk factors relevant to its non-invasive ventilation, sleep therapy, oxygen therapy, staffing, and related activities.
Viemed also files frequent current reports on Form 8-K to disclose material events. Recent 8-K filings have covered quarterly and year-to-date financial results, the completion of a share repurchase program, the acquisition of Lehan’s Medical Equipment, and amendments to the company’s credit agreement that extend certain term loan commitment expiration dates and provide technical changes. Some 8-K filings also furnish investor presentations and financial supplements used in communications with analysts and investors.
On this page, users can review Form 4 and other insider transaction filings, where available, alongside periodic and current reports. Stock Titan’s AI tools summarize lengthy filings, highlight key sections, and surface items such as changes to credit facilities, capital allocation actions, and updates to financial guidance that Viemed has chosen to disclose. Real-time updates from EDGAR ensure that new Viemed filings appear promptly, while AI-generated insights are designed to make the company’s regulatory record more accessible to both experienced and newer investors.
Viemed Healthcare General Counsel Jeremy Trahan reported multiple equity compensation transactions. On January 17, 2026, 4,884 restricted stock units and 1,221 cash-settled phantom share units vested, resulting in the acquisition of the same number of common shares. To cover tax obligations tied to the RSU vesting, 1,595 common shares were withheld at a per share value of $7.33, leaving 28,792 common shares held directly after the transactions.
On January 19, 2026, Trahan was granted 50,360 new restricted stock units and 12,590 phantom share units. Both awards vest in three equal annual installments beginning on the first anniversary of their grant date. Each RSU represents a right to receive one common share, while each phantom share represents the cash value of one common share on the vesting date.
Viemed Healthcare, Inc. reported a Third Amendment to its Credit Agreement with Regions Bank and other lenders. The change extends the Borrower’s delayed draw term loan commitment expiration date to November 29, 2026, from November 29, 2025, with additional technical amendments. This keeps the facility available for an extra year under the amended terms.
The company also made an Investor Deck Presentation available and may use it in discussions with investors and analysts. As indicated, this presentation and related Item 7.01 information are furnished, not filed, under the Exchange Act.
Viemed Healthcare (VMD) reported Q3 results showing continued top-line growth alongside active capital deployment. Revenue reached $71.9 million, up from $58.0 million a year ago, driven by ventilator rentals and expanding equipment sales and services. Gross profit was $41.3 million versus $34.4 million. Net income attributable to the company was $3.5 million (diluted EPS $0.09) compared with $3.9 million (EPS $0.10) last year as operating costs rose with growth and integration.
Year-to-date, revenue totaled $194.1 million vs. $163.6 million, and diluted EPS was $0.23 vs. $0.17. Operating cash flow was strong at $33.5 million. The company closed the Lehan Drugs acquisition on July 1 for $28.7 million, adding goodwill of $25.5 million. Debt increased under the 2022 facilities to $21.1 million from $4.6 million at year-end, while cash ended the quarter at $11.1 million. Viemed repurchased 1,976,441 shares for $13.6 million under its 2025 program, reducing the quarter-end share count to 38,017,907. On October 29, the company repaid $5.0 million on its revolver.
Viemed Healthcare (VMD) furnished an 8-K to announce its financial results for the three and nine months ended September 30, 2025. The company provided a press release and a Financial Supplement as exhibits.
The materials are furnished under Item 2.02 and, under General Instruction B.2, are not deemed filed or subject to Section 18 liabilities. Exhibits include the press release (99.1) and Financial Supplement (99.2), both dated November 5, 2025.
Viemed Healthcare, Inc. announced on September 23, 2025 that it has completed its previously authorized share repurchase program. The company repurchased a total of 1,976,441 common shares for an aggregate purchase price of approximately $13.2 million, before applicable taxes. The announcement was issued via a press release furnished as Exhibit 99.1 to the Current Report and is incorporated by reference. The filing notes the press release and related Item 7.01 information are furnished and not "filed" for purposes of Section 18 of the Exchange Act.
On 08/22/2025 Viemed Healthcare director and General Counsel Jeremy Trahan experienced equity award activity tied to prior grants. 2,986 cash-settled phantom share units vested and were reported as a cash settlement and simultaneous disposition of the underlying shares at a per-share value of $7.31. 5,971 Restricted Stock Units vested and converted into common shares, with 1,634 of those shares withheld to satisfy tax withholding. The reporting person holds 25,503 common shares following these transactions.
Kaushal Nitin, a director of Viemed Healthcare, Inc. (VMD), reported equity awards and increases in beneficial ownership. The filing shows transactions on August 19–20, 2025 in which the reporting person acquired 15,732 common shares and received restricted stock unit grants totaling 34,518 RSUs across two grant dates. One RSU grant from August 20, 2024 vested August 20, 2025 and corresponds to 15,732 shares; a separate RSU grant on August 19, 2025 vests August 19, 2026 for 18,786 shares. Following the reported transactions, the filing lists 142,575 common shares as beneficially owned by the reporting person. The form is signed by an attorney-in-fact.
Timothy Smokoff, a director of Viemed Healthcare, Inc. (VMD), received equity awards in August 2025. The Form 4 shows grants and the resulting ownership changes: 15,732 restricted stock units (RSUs) were reported as acquired on 08/20/2025 and 15,029 RSUs plus 3,757 phantom share units were acquired on 08/19/2025. After the 08/20/2025 transaction the filing shows the reporting person beneficially owned 95,518 common shares. The RSUs granted vest on specified future dates, and each phantom share represents a right to receive the cash value of one common share at vesting.
Randy E. Dobbs, a director of Viemed Healthcare, Inc. (VMD), reported changes in his beneficial ownership of the issuer's common stock on transactions dated 08/19/2025 and 08/20/2025. The filing shows a grant and vesting activity: Restricted Stock Units (RSUs) and Phantom Share Units were granted on 08/19/2025 (16,763 RSUs and 4,191 phantom units) that vest on 08/19/2026, and RSUs granted on 08/20/2024 that vest on 08/20/2025 are referenced in the explanations.
The reported result of the 08/20/2025 activity is an acquisition entry of 17,784 common shares (code M) and a reported total of 125,490 shares beneficially owned following the reported transaction(s). The filing was signed by an attorney-in-fact on 08/20/2025.
Sabrina Heltz, a director of Viemed Healthcare, Inc. (VMD), reported equity awards and changes in beneficial ownership in August 2025. The Form 4 shows grants and vesting events: on 08/19/2025 she was granted 15,029 restricted stock units (RSUs) that vest on 08/19/2026 and 3,757 phantom share units that vest on 08/19/2026. On 08/20/2025 a previously awarded 15,732 RSUs vested and were acquired, and after the reported transactions she beneficially owned 67,491 common shares. Phantom shares pay cash based on the issuer's share price at vesting. The filing was signed by an attorney-in-fact on behalf of the reporting person.